BioNTech, BMS tout first global data for PD-L1xVEGF bispecific in small cell lung cancer, set phase 3 dose
Bristol Myers Squibb and BioNTech reported promising global Phase 2 data for a PD-L1×VEGF bispecific drug in first-line extensive-stage small cell lung cancer.
The therapy showed a 76.3% overall response rate with manageable safety, comparing favorably to the existing standard of care in this setting. “I think it supports our approach to move into phase 3, which is ongoing,” said Bryan Campbell, BMS’ head of program leadership of hematology, oncology and cell therapy. “And I also think it supports the potential of this drug to set a new standard of care in small cell extensive-stage small cell lung cancer.”
This development could help set a new standard of care in small cell lung cancer, highlighting how Bristol Myers Squibb’s global partnerships are advancing innovation in oncology.